Literature DB >> 20434549

The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.

Lediya Cheru1, Yimin Wu, Ababacar Diouf, Samuel E Moretz, Olga V Muratova, Guanhong Song, Michael P Fay, Louis H Miller, Carole A Long, Kazutoyo Miura.   

Abstract

Plasmodium falciparum surface protein 25 (Pfs25) is a candidate for transmission-blocking vaccines (TBVs). Anti-Pfs25 antibodies block the development of oocysts in membrane-feeding assays and we have shown the activity correlates with antibody titer. In this study, we purified Pfs25-specific IgGs to convert antibody titer to microg/mL and determined the amount of antibody required to inhibit 50% of oocyst development (IC(50)). The IC(50) were, 15.9, 4.2, 41.2, and 85.6microg/mL for mouse, rabbit, monkey and human, respectively, and the differences among species were significant. Anti-Pfs25 sera from rabbit, monkey and human showed different patterns of competition against 6 mouse monoclonal antibodies, and the avidity of antibodies among four species were also different. These data suggests that information obtained from animal studies which assess efficacy of TBV candidates may be difficult to translate to human immunization.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20434549      PMCID： PMC2880321          DOI： 10.1016/j.vaccine.2010.04.036

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  27 in total

1.  Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum.

Authors:  Y P Shi; M P Alpers; M M Povoa; A A Lal
Journal:  Mol Biochem Parasitol       Date:  1992-01       Impact factor: 1.759

2.  Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum.

Authors:  D C Kaslow; I A Quakyi; D B Keister
Journal:  Mol Biochem Parasitol       Date:  1989-01-01       Impact factor: 1.759

3.  Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.

Authors:  Kazutoyo Miura; Hong Zhou; Samuel E Moretz; Ababacar Diouf; Mahamadou A Thera; Amagana Dolo; Ogobara Doumbo; Elissa Malkin; David Diemert; Louis H Miller; Gregory E D Mullen; Carole A Long
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies.

Authors:  I A Quakyi; R Carter; J Rener; N Kumar; M F Good; L H Miller
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

Review 5.  Current status of malaria and potential for control.

Authors:  R S Phillips
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

6.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.

Authors:  Pedro L Alonso; Jahit Sacarlal; John J Aponte; Amanda Leach; Eusebio Macete; Jessica Milman; Inacio Mandomando; Bart Spiessens; Caterina Guinovart; Mateu Espasa; Quique Bassat; Pedro Aide; Opokua Ofori-Anyinam; Margarita M Navia; Sabine Corachan; Marc Ceuppens; Marie-Claude Dubois; Marie-Ange Demoitié; Filip Dubovsky; Clara Menéndez; Nadia Tornieporth; W Ripley Ballou; Ricardo Thompson; Joe Cohen
Journal:  Lancet       Date:  2004 Oct 16-22       Impact factor: 79.321

7.  The reservoir of Plasmodium falciparum malaria in a holoendemic area of western Kenya.

Authors:  A K Githeko; A D Brandling-Bennett; M Beier; F Atieli; M Owaga; F H Collins
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Jul-Aug       Impact factor: 2.184

8.  Heterogeneity in patterns of malarial oocyst infections in the mosquito vector.

Authors:  G F Medley; R E Sinden; S Fleck; P F Billingsley; N Tirawanchai; M H Rodriguez
Journal:  Parasitology       Date:  1993-06       Impact factor: 3.234

9.  Relationship between prevalence and intensity of Plasmodium falciparum infection in natural populations of Anopheles mosquitoes.

Authors:  P F Billingsley; G F Medley; D Charlwood; R E Sinden
Journal:  Am J Trop Med Hyg       Date:  1994-09       Impact factor: 2.345

10.  Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.

Authors:  P J Barr; K M Green; H L Gibson; I C Bathurst; I A Quakyi; D C Kaslow
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307
View more
  38 in total

1.  Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.

Authors:  Nicholas J MacDonald; Vu Nguyen; Richard Shimp; Karine Reiter; Raul Herrera; Martin Burkhardt; Olga Muratova; Krishan Kumar; Joan Aebig; Kelly Rausch; Lynn Lambert; Nikiah Dawson; Jetsumon Sattabongkot; Xavier Ambroggio; Patrick E Duffy; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

2.  Salmonella flagellin acted as an effective fusion partner for expression of Plasmodium falciparum surface protein 25 in Escherichia coli.

Authors:  Feng Qian; Mengmeng Li; Yong Chen; Lin Jiang; Huji Xu
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

Review 3.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

4.  A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits.

Authors:  David H Mulama; Lorraine Z Mutsvunguma; Jennifer Totonchy; Peng Ye; Joslyn Foley; Gabriela M Escalante; Esther Rodriguez; Ramina Nabiee; Murali Muniraju; Felix Wussow; Anne K Barasa; Javier Gordon Ogembo
Journal:  Vaccine       Date:  2019-06-11       Impact factor: 3.641

5.  ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum.

Authors:  Kazutoyo Miura; Bingbing Deng; Yimin Wu; Luwen Zhou; Thao P Pham; Ababacar Diouf; Chia-Kuei Wu; Shwu-Maan Lee; Jordan L Plieskatt; Merribeth J Morin; Carole A Long
Journal:  Vaccine       Date:  2019-03-05       Impact factor: 3.641

Review 6.  Immune Responses in Malaria.

Authors:  Carole A Long; Fidel Zavala
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

7.  The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania.

Authors:  Teun Bousema; Will Roeffen; Hinta Meijerink; Harry Mwerinde; Steve Mwakalinga; Geert-Jan van Gemert; Marga van de Vegte-Bolmer; Frank Mosha; Geoffrey Targett; Eleanor M Riley; Robert Sauerwein; Chris Drakeley
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

8.  Transmission-blocking interventions eliminate malaria from laboratory populations.

Authors:  A M Blagborough; T S Churcher; L M Upton; A C Ghani; P W Gething; R E Sinden
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Immunisation against a serine protease inhibitor reduces intensity of Plasmodium berghei infection in mosquitoes.

Authors:  Andrew R Williams; Sara E Zakutansky; Kazutoyo Miura; Matthew D J Dicks; Thomas S Churcher; Kerry E Jewell; Aisling M Vaughan; Alison V Turner; Melissa C Kapulu; Kristin Michel; Carole A Long; Robert E Sinden; Adrian V S Hill; Simon J Draper; Sumi Biswas
Journal:  Int J Parasitol       Date:  2013-07-18       Impact factor: 3.981

10.  Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays.

Authors:  Kazutoyo Miura; Bingbing Deng; Gregory Tullo; Ababacar Diouf; Samuel E Moretz; Emily Locke; Merribeth Morin; Michael P Fay; Carole A Long
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.